The Medical Services Advisory Committee (MSAC) regularly seeks targeted feedback from Australian Genomics on genetic and genomic-related applications for public funding of medical services and technologies. Australian Genomics develops feedback for submissions by consulting with expert members drawn from its 450-strong network of professionals, to put forward unified, evidence-based submissions.
April 2021
Response to MSAC Application 1658: ‘Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, for access to PBS Olaparib’.
Response to MSAC Application 1660: ‘Diagnostic testing for mesenchymal-epithelial transition (MET) Exon 14 (METex14) skipping alterations in non-small cell lung cancer (NSCLC) to determine Pharmaceutical Benefits Scheme eligibility for tepotinib treatment’.
August 2021
Response to MSAC Application 1669: ‘KRAS G12C variant testing to determine eligibility for PBS subsidized sotorasib second-line therapy in patients with locally advanced or metastatic NSCLC’.
Response to MSAC Application 1671: ‘Carrier screening for severe monogenic disorders’.
November 2021
Response to MSAC Application 1675: ‘Whole Genome Sequencing for the diagnosis of mitochondrial disease’.
Response to MSAC Application 1680: ‘Genetic testing for childhood hearing impairment’.
Response to MSAC Application 1684: ‘Genetic testing for variants associated with haematological malignancies’.
July 2022
Response to MSAC Application MSAC application 1710: ‘Newborn bloodspot screening for X-ALD’.
October 2022
Response to MSAC Application 1721: ‘Small gene panel testing for non-small cell lung carcinoma.’
February 2023
Response to MSAC Application 1658.1: ‘Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, for access to PBS Olaparib’.
Response to MSAC Application 1726: ‘Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, for access to PBS niraparib’.
November 2023
Response to MSAC Application 1760: ‘DPYD genotyping to predict fluoropyrimidine-induced toxicity’.
February 2024
Response to MSAC Application 1765: ‘Amendment of MBS items 73303 and 73304 (BRCA1/2 mutation testing in patients with metastatic castration-resistant prostate cancer) to include talazoparib’.
March 2024
Response to MSAC Application 1774: ‘Newborn bloodspot screening for glycogen storage disease, Type II (Pompe disease)’.
Response to MSAC Application 1775: ‘Newborn bloodspot screening for mucopolysaccharidosis, Type 1 (MPS I)’.
Response to MSAC Application 1776: ‘Newborn bloodspot screening for mucopolysaccharidosis, Type II (MPS II)’.
July 2024
Response to MSAC Application 1782: ‘Genetic testing to detect estrogen receptor 1 (ESR1) mutations in patients with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer, to determine eligibility for treatment with PBS subsidised elacestrant’.